Business
Symposium: Shortwave Presenting Clinical Research
Shortwave Life Sciences Plc will be a Gold Partner at the PSYCH Symposium on December 4, 2025, where Chief Medical Advisor Dr. Nadya Lisovoder will present emerging clinical research on a new human study for anorexia treatment, outlining the rationale for their feasibility study exploring psychedelic-assisted therapy for severe anorexia nervosa and early findings from their psilocybin-based buccal film program. The company's participation underscores its focus on research that advances clinical understanding and informs future regulatory assessment, positioning Shortwave within a group of organizations advancing psychedelic medicine. Disclaimer*
About this update from Tomahawk Metals Plc
[{"type":"text","content":"\n\nSHORTWAVE LIFE SCIENCES PLC\n \n(\"Shortwave\" or \"the Company\")\n \n \n2 December 2025\n \nPSYCH Symposium London 2025: Shortwave Life Sciences to Present Emerging Clinical Research as Gold Partner\n \nShortwave Life Sciences plc announces that it will serve as a Gold Partner at the PSYCH Symposium, taking place on 4 December 2025 at Conway Hall, London. The Symposium is recognised as one of the leading international forums for scientific and clinical discussion on psychedelic-based treatments. It brings together senior clinicians, neuroscientists, policy specialists, research institutions and programme leaders from Europe and North America to examine emerging data, regulatory developments and future pathways for patient access.\n \nAs part of the official programme, Dr Nadya Lisovoder, Chief Medical Advisor at Shortwave Life Sciences, will deliver a session titled Designing Breakthroughs: A New Human Study for Anorexia Treatment. Her presentation will outline the rationale for Shortwave's feasibility study exploring psychedelic-assisted therapy for severe anorexia nervosa. This will include current understanding of neural circuit dysfunction, rigid cognitive patterns and anxiety-driven reward systems associated with chronic anorexia, as well as early findings from Shortwave's psilocybin based buccal film programme, which is designed to support controlled delivery and improved tolerability in medically fragile patient groups.\n \nFollowing her presentation, Dr Lisovoder will join Kate Spicer of The Sunday Times for a conversation focused on the clinical and regulatory barriers that have limited innovation in anorexia treatment and the implications of new research for patients and families.\n \nDr Lisovoder commented: \"PSYCH Symposium brings together the leading clinical and scientific figures shaping the development of psychedelic-based treatments. Anorexia nervosa remains one of the most lethal psychiatric conditions, and there is an ongoing need for treatments grounded in strong science. Our research aims to understand the mechanisms that may support change in a condition defined by chronic relapse and limited therapeutic options. Presenting this work at PSYCH allows us to engage with colleagues who are generating important evidence across multiple therapeutic areas.\"\n&nb...